Over security concern, Eli Lilly stops preliminary of counter acting agent drug Trump promoted as COVID-19 ‘cure’

Eli Lilly and Co said on Tuesday that the legislature supported clinical preliminary of its COVID-19 neutralizer treatment like one taken by U.S. President Donald Trump has been delayed on account of a security concern. Trump promoted the Lilly drug, alongside the neutralizer treatment from Regeneron Pharmaceuticals Inc that he got for his COVID-19, as commensurate to a fix in a video he posted a week ago. The declaration comes one day after Johnson and Johnson said it had to delay a huge prominent preliminary of its exploratory Covid antibody…

Read More